Division of Plastic and Reconstructive Surgery, David Geffen School of Medicine at University of California Los Angeles, 200 Medical Plaza, Suite 465, Los Angeles, CA 90095-6960, USA.
Aesthetic Plast Surg. 2012 Jun;36(3):704-13. doi: 10.1007/s00266-011-9835-4. Epub 2011 Nov 9.
With adipose-derived stem cells (ASCs) at the forefront of research and potential clinical applications, it is important that clinicians be able to distinguish them from the fat grafting currently used clinically and to understand how the two approaches relate to one another. At times, there has been confusion in clinically considering the two therapies to be the same. This report is aimed at distinguishing clearly between fat grafting and ASC therapy with regard to the indications, harvesting, processing, application techniques, outcomes, and complications. Findings have shown that autologous fat transfer, a widely used procedure for soft tissue augmentation, is beneficial for reconstructive and cosmetic procedures used to treat patients with volume loss due to disease, trauma, congenital defects, or the natural process of aging. On the other hand, ASCs have been identified as an ideal source of cells for regenerative medicine, with the potential to serve as soft tissue therapy for irradiated, scarred, or chronic wounds. Recent advances in tissue engineering suggest that the supplementation of fat grafts with ASCs isolated in the stromal vascular fraction may increase the longevity and quality of the fat graft. Research suggests that ASC supplementation may be a great clinical tool in the future, but more data should be acquired before clinical applications.
脂肪来源的干细胞（ASCs）是研究和潜在临床应用的前沿，临床医生能够将其与目前临床上使用的脂肪移植区分开来，并了解这两种方法之间的关系非常重要。有时，临床上会混淆这两种疗法，认为它们是相同的。本报告旨在明确区分脂肪移植和 ASC 疗法在适应证、采集、处理、应用技术、结果和并发症方面的区别。研究结果表明，自体脂肪移植是一种广泛用于软组织增强的手术，对于因疾病、创伤、先天性缺陷或自然衰老过程导致的体积减少的患者，这种手术对于重建和美容手术是有益的。另一方面，ASCs 已被确定为再生医学的理想细胞来源，有可能成为辐射、瘢痕或慢性伤口的软组织治疗方法。组织工程学的最新进展表明，将 ASC 从基质血管部分分离出来补充到脂肪移植中，可能会增加脂肪移植的寿命和质量。研究表明，ASC 补充可能是未来的一个重要临床工具，但在临床应用之前，应该获得更多的数据。
